An overview of regular dialysis treatment in Japan (as of 31 December 2004).
A statistical survey of 3932 nationwide hemodialysis (hereafter, dialysis) facilities was carried out at the end of 2004, and 3882 facilities (98.73%) responded. The population undergoing dialysis at the end of 2004 was 248 166, an increase of 10 456 patients (4.4%) from that at the end of 2003. The number of dialysis patients per million people was 1943.5. The crude death rate of dialysis patients from the end of 2003 to the end of 2004 was 9.4%. The mean age of patients who underwent dialysis in 2004 was 65.8 years, and that of the total dialysis population was 63.3 years. The percentage distribution of patients who underwent dialysis according to a newly underlying disease showed that 41.3% of patients had diabetic nephropathy and 28.1% had chronic glomerulonephritis. The frequency of calcium carbonate use for dialysis patients was 75.1% and that of sevelamer hydrochloride use was 26.2%. The frequency of sevelamer hydrochloride use does not necessarily have a strong correlation with the dose of calcium carbonate. Patients who received high doses of sevelamer hydrochloride tended to have a low concentration of arterial blood HCO(3-). Approximately 15% of dialysis patients used an intravenous vitamin D preparation, generally maxacalcitol. The longer the patients had been on dialysis, the higher the frequency of use of an intravenous vitamin D preparation. When the concentration of serum intact parathyroid hormone (PTH) was more than 200 pg/mL, the frequency of use of an orally administered vitamin D preparation decreased; but that of intravenous vitamin D preparation increased. The percentage of dialysis patients who received percutaneous ethanol injection therapy (PEIT) was 1.4%. The percentage was more than 50% in the patients who had been on dialysis for more than 10 years. The percentage of patients who received PEIT again was 35.0%. The percentage of patients who had been on hemodialysis for more than 10 years and received PEIT again was more than 50%.
Nakai
Shigeru
S
Patient Registration Committee, Japanese Society for Dialysis Therapy, Tokyo, Japan.
Wada
Atsushi
A
Kitaoka
Tateki
T
Shinzato
Takahiro
T
Nagura
Yuji
Y
Kikuchi
Kenjiro
K
Masakane
Ikuto
I
Shinoda
Toshio
T
Yamazaki
Chikao
C
Sakai
Rumi
R
Marubayashi
Seiji
S
Morita
Osamu
O
Iseki
Kunitoshi
K
Usami
Takeshi
T
Kimata
Naoki
N
Suzuki
Kazuyuki
K
Tabei
Kaoru
K
Fushimi
Kiyohide
K
Miwa
Naoko
N
Yauchi
Mitsuru
M
Wakai
Kenji
K
Akiba
Takashi
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D015312:Hemodialysis Solutions; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000601:surgery; D007564:Japan / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000401:mortality / Q000706:statistics & numerical data*; D015996:Survival Rate; D014807:Vitamin D / Q000008:administration & dosage
D015312:Hemodialysis Solutions; D014807:Vitamin D